Study: Morphine-Like Drug Stronger, Longer-Lasting Than Standard Morphine

A little-known morphine-like drug could be more potent, longer-lasting and less likely to cause constipation than standard morphine, according to a study led by Loyola University Health System anesthesiologist Joseph Holtman Jr., MD.

Advertisement

The drug, morphine-6-0-sulfate, has a similar chemical structure to standard morphine and “demonstrated potential clinical advantages” over standard morphine in a study performed on rats, according to a health system release.

Dr. Holtman and his colleagues tested standard morphine and morphine-6-0 sulfate on rats. The animals received the drugs by mouth, by IV and by injection in the space surrounding the spinal cord and then underwent several well-established tests to determine sensitivity to pain.

The study showed morphine-6-0-sulfate to be more potent than standard morphine for neuropathic and inflammatory pain and less likely to cause constipation, a problem that causes some patients to limit their use of standard morphine.

Read the Loyola University Health System release on the study on morphine-6-0-sulfate.

Read more on anesthesia:

Propofol Now Available From PharMEDium Services

-Pain Clinic License Revoked After Anesthesiologist Medical Director Contacts State

10 Most-Read Anesthesia News Stories of 2010

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in Anesthesia

Advertisement

Comments are closed.